Trial Profile
A Phase II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Gemcitabine Monotherapy in Patients With Advanced Inoperable or Metastatic Pancreatic Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs BLI 1401 (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Rgene Corporation
- 16 Nov 2023 Planned End Date changed from 30 Jun 2025 to 30 Jun 2026.
- 16 Nov 2023 Planned primary completion date changed from 30 Apr 2025 to 30 Apr 2026.
- 16 Nov 2023 Planned initiation date changed from 1 Jul 2023 to 1 Jul 2024.